Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06650761 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of CDX-622
A Phase 1 study of Healthy Participants, sponsored by Celldex Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT06650761: Active Phase 1 study of Healthy Participants, sponsored by Celldex Therapeutics.
NCT06650761 is a Phase 1 study of Healthy Participants that is active but no longer recruiting, run by Celldex Therapeutics. The registered enrollment target is 85 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06650761, a Phase 1 study of Healthy Participants, is active but no longer recruiting, sponsored by Celldex Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to determine the safety of CDX-622 in healthy participants.
Primary Outcome
To evaluate the safety profile as determined by the incidence of adverse events in single or multiple ascending doses of CDX-622 or placebo comparator in healthy participants.
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG CDX-622
Study Locations (1)
Arizona
- Celerion, Inc. - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What the registry record for NCT06650761 still lists
NCT06650761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (31% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT06650761 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06650761 about?
NCT06650761 is a clinical study titled "A Phase I Study of CDX-622". This is a study to determine the safety of CDX-622 in healthy participants.
What is the current status of trial NCT06650761?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2024-11-01. Estimated completion is 2026-04.
What conditions does trial NCT06650761 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06650761?
The interventions under investigation include: Normal Saline (DRUG), CDX-622 (DRUG).
Who is sponsoring clinical trial NCT06650761?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06650761 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06650761's enrollment target sits among peer trials
85 29th of 119 higher than 91 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI